Corvus Pharmaceuticals, Inc.
CRVS
$6.94
-$0.31-4.30%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.02M | 8.45M | 8.16M | 7.66M | 7.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.54M | 31.22M | 27.55M | 25.07M | 23.38M |
| Operating Income | -35.54M | -31.22M | -27.55M | -25.07M | -23.38M |
| Income Before Tax | -45.14M | -41.40M | -62.29M | -56.83M | -22.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.14 | -41.40 | -62.29 | -56.83 | -22.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.14M | -41.40M | -62.29M | -56.83M | -22.62M |
| EBIT | -35.54M | -31.22M | -27.55M | -25.07M | -23.38M |
| EBITDA | -35.45M | -31.13M | -27.46M | -24.98M | -23.28M |
| EPS Basic | -0.67 | -0.64 | -0.97 | -0.93 | -0.45 |
| Normalized Basic EPS | -0.42 | -0.40 | -0.60 | -0.58 | -0.28 |
| EPS Diluted | -1.02 | -0.98 | -0.97 | -0.93 | -0.45 |
| Normalized Diluted EPS | -0.43 | -0.41 | -0.60 | -0.58 | -0.28 |
| Average Basic Shares Outstanding | 284.95M | 266.88M | 243.80M | 224.49M | 206.76M |
| Average Diluted Shares Outstanding | 287.97M | 269.91M | 243.80M | 224.49M | 206.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |